Drug Interactions between eculizumab and Gamimune N 10%

Consumer information for this interaction is not currently available.

ADJUST DOSE: According to the prescribing information for eculizumab, intravenous immunoglobulin (IVIg) treatment may interfere with the endosomal neonatal Fc receptor (FcRn) recycling mechanism of monoclonal antibodies such as eculizumab, which may lead to decreased serum concentrations and reduced effectiveness of eculizumab. The clinical significance is unknown. Drug interaction studies have not been conducted with eculizumab in patients treated with IVIg.

MANAGEMENT: Due to the potential for reduced eculizumab effectiveness, close clinical monitoring is recommended if coadministration with IVIg is clinically necessary. According to some authorities, administering a supplemental dose of eculizumab in patients receiving concomitant IVIg is advised. The supplemental dose of eculizumab is dependent on the most recent dose of eculizumab. For patients receiving eculizumab doses less than or equal to 600 mg, a supplemental eculizumab dose of 300 mg per IVIg cycle should be administered. For patients receiving eculizumab doses greater than or equal to 900 mg, a supplemental eculizumab dose of 600 mg per IVIg cycle should be administered. The supplemental eculizumab dose should be administered as soon as possible after the IVIg cycle. Additional consultation with individual package labeling, as well as relevant institutional protocols, may be advisable for further guidance.